This article first appeared on GuruFocus .
-
Product Sales:EUR64 million in H1 2026, down from EUR91 million in H1 2025.
-
Ixiaro Sales:EUR44 million, down from EUR54.7 million year-over-year, impacted by distributor transition in Germany and timing of US Department of Defense shipments.
-
Ducoral Sales:EUR14.7 million, down from EUR17.4 million in H1 2025, affected by prior-year one-time outbreak supply and distributor transition.
-
Ixchiq Sales:EUR4.4 million, down from EUR7.5 million, including first shipment to Brazilian partner Instituto Butantan.
-
Third-Party Product Sales:EUR1 million, down from EUR11.4 million, due to planned expiration of distribution agreements.
-
Total Revenues:EUR65.8 million versus EUR97.6 million in H1 2025.
-
Cost of Goods and Services:EUR59.5 million, up from EUR47.2 million, including EUR9.7 million in cancellation fees and EUR4.5 million inventory impairment.
-
Ixiaro Gross Margin:56.4%, down from 65.5% in the prior year.
-
Ducoral Gross Margin:24.7%, down from 52.9% in H1 2025.
-
Research and Development Expense:EUR30.2 million, down from EUR32.4 million.
-
Marketing and Distribution Expense:EUR13.5 million, down from EUR20.3 million.
-
G&A Expense:EUR15.4 million, down from EUR19 million.
-
Operating Loss:EUR49.9 million, compared to a loss of EUR16.8 million in H1 2025.
-
Adjusted EBITDA Loss:EUR40.1 million, compared to a loss of EUR6 million in the prior year.
-
Cash Position:EUR121.5 million at June 30, 2026, up from EUR109.6 million at end of fiscal year 2025.
-
Cash Used in Operations:EUR13.7 million in H1 2026, compared to EUR10.9 million in H1 2025.
-
FY 2026 Guidance:Product sales of EUR135 million to EUR150 million and total revenues of EUR145 million to EUR160 million.
Release Date: August 13, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Valneva SE ( INRLF ) ended the first half of 2026 with a strong cash position of over EUR120 million, bolstered by disciplined cash management and proceeds from a recent offering.
-
Pfizer remains highly positive on the Lyme disease vaccine candidate, expecting regulatory decisions within the next 12 months, which could unlock significant value.
-
The company has implemented a broad restructuring program expected to generate positive P&L and cash flow impacts in the second half of 2026 and beyond.
-
Valneva SE ( INRLF ) reaffirmed its full-year 2026 guidance for product sales of EUR135-150 million and total revenues of EUR145-160 million, indicating confidence in its base business.
-
The locally manufactured Chikungunya vaccine in Brazil by partner Butantan has been approved, with over 50,000 people already vaccinated in a pilot campaign, opening a significant market opportunity.
-
The company is advancing its Shigella vaccine candidate, with results from two key studies expected in the coming months, potentially expanding its pipeline.
Negative Points
-
Valneva SE ( INRLF ) reported a significant operating loss of EUR49.9 million in the first half of 2026, a sharp decline from the EUR16.8 million loss in the prior year.
-
Total product sales decreased to EUR64 million from EUR91 million in the first half of 2025, driven by distributor transitions, product phasing, and geopolitical factors.
-
The company recorded non-recurring charges, including a EUR9.7 million provision for cancellation fees and a EUR4.5 million non-cash impairment of excess inventory, impacting gross margins.
-
Gross margins for key products like Ixiaro and Ducoral declined significantly due to lower volumes, manufacturing schedule changes, and higher failed batch costs.
-
The future strategic direction and potential for financial self-sustainability are heavily dependent on the successful regulatory approval and commercialization of the Lyme disease vaccine.
-
Sales of the Chikungunya vaccine (Ixchiq) remain slow in the travel market, prompting the company to evaluate a strategic shift towards endemic markets.
Q & A Highlights
Q: Can you provide any more detail on the regulatory update for the Lyme disease vaccine, given Pfizer's optimism about a decision in the next 12 months? A: Thomas Lingelbach (CEO): Pfizer is making very good progress with the regulatory agencies, and we hope to announce next steps soon. That's all we can say at this moment in time specifically.
Q: Could you elaborate on the potential scenarios for the Lyme program, such as running another Phase 3 program or post-marketing surveillance, and how that would factor into capital allocation? A: Thomas Lingelbach (CEO): The existing agreement with Pfizer includes Valneva sharing development costs to licensure. Everything beyond licensure is currently not part of the contractual agreement. Whether we will further invest in Lyme on those points may be discussed later, but definitely not before we see the product licensed.
Q: Can you provide more color on what is gating the Shigella update, and should we expect clarity on the path forward when data is disclosed? A: Thomas Lingelbach (CEO): We've had a few delays on the program, as the studies are still conducted by NEMATech, which was recently acquired by LIDI. We are in the final steps of data validation and analysis. The human challenge study will give us a clear understanding of efficacy, and the immunogenicity study in children will provide safety data. We will take both data packages together and decide on next development steps, announcing them either with the data or very shortly thereafter.
Q: For the U.S. and European regulatory paths for Lyme, are they moving in parallel or sequentially? A: Thomas Lingelbach (CEO): Both activities are progressing nicely and are independent processes. At this moment, I would assume Europe probably goes first, but Pfizer is working closely with the FDA in support of its planned BLA submission.
Q: Can you share any details on why Pfizer decided to file in Europe first, and are there differences in how the European Agency and FDA look at vaccine data? A: Thomas Lingelbach (CEO): We can confirm Pfizer filed with the European Medicines Agency. I would not speculate on why one is earlier than the other. The data are the same, and all agencies look at the totality of clinical evidence, risk-benefit, and health economic benefits. I have never seen material differences in how the two regulatory bodies handle applications.
Q: It seems you are gravitating toward a more R&D-driven identity. To what extent does this strategic direction depend on Lyme being successful? A: Thomas Lingelbach (CEO): The key purpose of our commercial business is to maximize cash generation and reinvest in R&D. The capacity to invest depends heavily on Lyme's success, as royalties would go straight to the bottom line, potentially making us financially self-sustainable. It's a very appealing strategy, but it's all about Lyme and depends on licensure and commercial success.
Q: Regarding the sale of the site in France, does this bring ongoing cost reduction beyond the proceeds? A: Thomas Lingelbach (CEO): As part of our restructuring program, we consolidated all R&D operations into Vienna and shut down operations in Nantes. This consolidation brings efficiency and cost reduction over time, with significant benefits to come, besides the proceeds from the building sale.
Q: How should we think about SG&A and R&D for the remainder of the year, and does the 25-35% reduction in OpEx guidance still hold? A: Peter Buehler (CFO): We expect continued efficiency in SG&A spend, and what you see in the first half is what we will continue to see. On R&D, we expect a decrease in costs in the second half. The guidance on cost reduction versus last year still holds true; we have not revised it.
Q: What is the realistic expectation for gross margin in the second half of 2026? A: Peter Buehler (CFO): There were many one-off and non-cash effects in the first half. In the second half, we clearly expect a much better gross margin. For the full year, we will probably not get exactly to last year's level, but we will get much closer, with a positive trend into 2027.
Q: How long might it be before the start of commercial sales of the locally manufactured Chikungunya vaccine in Brazil? A: Thomas Lingelbach (CEO): Our partner is in the midst of launch planning, so it's too early to discuss commercial prospects. There is a clear desire to include the vaccine in the healthcare system, and we expect this to become a very significant opportunity, but it's too early to provide numbers.
Q: How long do you expect the pilot vaccination program in Brazil to continue? A: Thomas Lingelbach (CEO): The program is owned by the Ministry of Health. The government's objective is a minimum of 100,000 people vaccinated to generate active pharmacovigilance data. This target could be reached by the latter part of the year.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
